Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

20150402 smb inno boot gatt


Published on

  • Be the first to comment

  • Be the first to like this

20150402 smb inno boot gatt

  1. 1. Presentation Radboud Innovatie BootCamp 2015 Rob Lips Nijmegen, 2 april 2015 GATT Technologies BV GATT-Patch Strategic or Financial investors? GATT™ synthetic polyoxazoline (POX) platform for surgical sealants and hemostats GATT-Tape GATT- Patch
  2. 2. Agenda From POX polymer to medical device business opportunity 14 April 2015 GATT Technologies BV 2 About GATT Technologies BV The GATT-Patch product opportunity The GATT-Patch industry opportunity Strategy and financing
  3. 3. Johan Bender MSc Prof Harry v Goor CEO, founder clinical partner serial entrepreneur About GATT founded with a clinical ambition 14 April 2015 GATT Technologies BV 3 “The GATT technology platform will enable medical device tapes and patches with specific properties optimized for the targeted clinical application” GATT Technologies BV : founded in 2011 by Johan Bender The unmet need : anastomotic leakage: 3-15% with mortality 2-3% The ambition : the GATT-Tape
  4. 4. About GATT GATT-Tape : technology and successful proofs of concept 14 April, 2015 4 Approved PEG (Polyethyleneglycol ) sealant products DuraSeal: CoSeal: Successful Proofs of Concept GATT-POX advantages over PEG  strong adhesion on wet tissue water tight < 1-2 minutes  GATT-Tape production Hot Melt Extrusion POX poly(2-oxazoline)s has additional benefits:  stronger adhesion  better tuneable functionality  non-brittle PEG POX + End and side chains + Versatile synthesis GATT Technologies BV
  5. 5. GATT-Tape needed milestones and financing 14 April, 2015 GATT Technologies BV 5 GATT Technologies BV Strategic Partner GATT Tape Technical Proof-of-Concept X M€ GATT Tape Pre-Clinical Studies GATT Tape Clinical Studies Milestone CE GATT Tape Market intro first Sales 0.X M€ X M€* X M€ X M€ 2015 2016 2018 * intended innovation loans 0.XM€ Financial Investors Subsidies/Loans Financial Investors ?
  6. 6. The large hemostatic and sealant market trend to (semi) synthetic medical devices 14 April 2015 6 product costs adhesion strength Hemostats Sealants *time to hemostasis medical device medicine 2005 Mechanical hemostats (1-10 min.)* PEG sealants (<2 min.)* GATT Technologies BV Fibrin powders (<3 min.)* Fibrin gels (<3 min.)* Fibrin spray sealants (<5-10 min.)* Fibrin patches (<3 min.)* POX GATT-Tape (seal)
  7. 7. POX GATT-Tape (seal) The product opportunity clinical need for cost-effective, high-end hemostats 14 April 2015 7 product costs adhesion strength Hemostats Sealants *time to hemostasis medical device medicine Fibrin patches (<3 min.)* 2005 Mechanical hemostats (1-10 min.)* 2014 PEG patches (<2 min.)* GATT Technologies BV POX GATT-Patch (<1 min)* GATT-Patch > equal/better than Baxter Hemopatch 2017
  8. 8. GATT-Patch cost effective solution in expanding market segment 14 April, 2015 8 The opportunity: Baxter HemoPatch slipstream BAXTER, recently introduced the Hemopatch (a sealing hemostat):  PEG-collagen based  hemostatic medical device  competitive pricing  The GATT-Patch will have equal or better characteristics than the BAXTER Hemopatch  Especially on the faster time to hemostasis (< 1 min.) and at least equal cost effectiveness.  The GATT-Patch will be an attractive and profitable completion of the product portfolio for most of the major vendors  expensive  time to hemostatis 3 min. The targeted GATT-Patch product GATT Technologies BV
  9. 9. The industry opportunity market shift to cost-effective, semi-synthetic medical devices 14 April 2015 9 product costs adhesion strength Hemostats Sealants *time to hemostasis medical device medicine Fibrin patches (<3 min.)* PEG patches (<2 min.)* POX GATT-Patch (<1 min)* 1 Mechanical hemostats (1-10 min.)* 2 GATT Technologies BV
  10. 10. The industry opportunity targeted companies and confirmed interest 14 April 2015 10 1. Market players with expensive fibrin hemostats:  a competitive high end “sealing” hemostat, is a must for their sales channels  the GATT POX technology will allow for a complete competitive, cost-effective hemostat portfolio 2. Market players with traditional mechanical hemostats:  enables shift of portfolio and expansion of business to attractive high-end GATT-Patch industry target Matrix: GATT Technologies BV
  11. 11. * <= level as PEG << lower than Fibrin The product opportunity Profitable turnover 14 April, 2015 11 Value chain Turnover The turnover potential for the GATT-Patch is estimated at 50-150M€ at a targeted 10-20% share in the high end market. First sales will start at the end of 2017 with a targeted sales turnover of 10-20M€ after 5 years GATT Technologies BV
  12. 12. GATT-Patch BV Strategy: separate legal entity with full business ownership 14 April, 2015 GATT Technologies BV 12 GATT Technologies BV  IP  POX technology platform  product development  supply of activated POX Strategic Partner  approved carrier + know-how  production  co-investment  (distribution) GATT Patch BV  business and product owner  exclusive rights on hemostat technology large OEM partners distributors* *independent and/or from strategic partner product supply
  13. 13. GATT-Patch BV deal construction for partnership GATT-Strategic Partner 14 April, 2015 GATT Technologies BV 13 GATT Technologies BV Strategic Partner GATT Patch BV Technical Proof-of-Concept GATT-Tech 100% X M€ GATT Patch BV Pre-Clinical Studies GATT-Tech 90% Partner 10% GATT Patch BV Milestone CE Clinical Studies GATT-Tech 75% Partner 25% GATT Patch BV Market intro operational sales endorsement studies GATT-Tech 50% Partner 50% 0.X M€ X M€* X M€ X M€ 2015-Q2 2016-Q2 2017 * intended innovation loans 0.XM€
  14. 14. GATT-Patch Strategic or Financial investors? GATT-Tape Financial Investor GATT- Patch Strategic Investor GATT Technologies BV Rob Lips